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A B S T R A C T
Purpose: Epilepsy is one of the most common manifestations in gliomas and has a severe effect on the life
expectancy and quality of life of patients. The aim of our study was to assess the potential connections
between clinicopathological factors and postoperative seizure.
Method: We retrospectively investigated a group of 147 Chinese high-grade glioma (HGG) patients with
preoperative seizure to examine the correlation between postoperative seizure and clinicopathological
factors and prognosis. Univariate analyses and multivariate logistic regression analyses were performed
to identify factors associated with postoperative seizures. Survival function curves were calculated using
the Kaplan–Meier method.
Results: 53 patients (36%) were completely seizure-free (Engel class I), and 94 (64%) experienced a
postoperative seizure (Engel classes II, III, and IV). A Chi-squared analysis showed that anaplastic
oligodendroglioma/anaplastic oligoastrocytoma (AO/AOA) (P = 0.05), epidermal growth factor receptor
(EGFR) expression (P = 0.0004), O6-methylguanine DNA methyltransferase (MGMT) expression
(P = 0.011), and phosphatase and tensin homolog (PTEN) expression (P = 0.045) were all signiﬁcantly
different. A logistic regression analysis showed that MGMT expression (P = 0.05), EGFR expression
(P = 0.001), and AO/AOA (P = 0.038) are independent factors of postoperative seizure. Patients with lower
MGMT and EGFR expression and AO/AOA showed more frequent instances of postoperative seizure.
Postoperative seizure showed no statistical signiﬁcance on overall survival (OS) and progression-free
survival (PFS).
Conclusion: Our study identiﬁed clinicopathological factors related to postoperative seizure in HGGs and
found two predictive biomarkers of postoperative seizure: MGMT and EGFR. These ﬁndings provided
insight treatment strategies aimed at prolonging survival and improving quality of life.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization (WHO) classiﬁes gliomas into
four grades, and grades III and IV are deﬁned as high-grade gliomas
(HGGs) [1]. Medical advances have improved the effectiveness of
surgery, radiation, and chemotherapeutic drugs. However, HGGs
are extremely invasive, and the prognosis of patients with HGGs
remains poor with median survival times of 22 months for AA
(anaplastic astrocytoma) and 12 months for GBM (glioblastoma)served.
P. Yang et al. / Seizure 35 (2016) 93–9994[2]. Thus, it is important to enhance the therapeutic efﬁcacy and
reduce the neurological symptoms induced by HGGs, such as
seizures, which signiﬁcantly affect quality of life [3]. It is essential
to identify patients at risk of developing a HGG-associated
postoperative seizure such that better targeted therapies can be
designed for controlling postoperative seizures and improving
patient prognosis [4].
Seizures are common in HGGs in the brain and are frequently an
initial symptom of this deadly disease [5–7]. Seizures are common
in diffuse gliomas, occurring in 50–90% of low-grade astrocytoma
patients and in 20–50% of glioblastoma patients [8]. The
pathogenesis of seizures induced by HGGs remains uncertain
and most likely differs from that of LGGs. Seizures have been
reported in 6% of patients with malignant glioma during the
postoperative period [9,10]. Thus, patients with brain tumours
need to take antiepileptic drugs (AEDs) after neurosurgery. When
uncontrolled, tumour-related epilepsy and antiepileptic drug
toxicities substantially contribute to neurological morbidity and
have a signiﬁcant effect on the patients’ quality of life (QOL) [11–
14]. Although epilepsy is more frequently observed in patients
with LGGs, it is more difﬁcult to control in patients with HGGs [15].
There is a vast difference between the pathogenesis of tumour-
related seizure and that of other types of seizure [16]. Although
patients with HGGs experience symptomatic postoperative
seizures, many patients do not experience postoperative seizures
despite exhibiting similar histology and performance status. Thus,
postoperative seizures cannot be entirely explained by tumour-
related or peritumoural factors. Instead, such seizures may result
from a complex interaction between tumour-related and genetic
factors [16].
Despite the frequency of postoperative seizures, factors
inﬂuencing seizures associated with HGGs have not been
addressed in a detailed manner. Thus, the purpose of the present
study was to identify the prognostic importance of postoperative
seizures as well as predictors of seizure control after surgical
resection. It is presently popular to investigate correlations
between tumour-related biomarkers and surgical outcomes.
Although previous studies [17–19] have identiﬁed some suscepti-
bility candidate biomarkers associated with seizure control after
surgery for LGGs, little is known regarding how the expression of
these biomarkers may inﬂuence postoperative seizure in patients
with HGGs. Here, we report our ﬁndings concerning postoperative
seizure obtained from a large retrospective single-centre series of
147 patients with WHO grade III and IV gliomas with epileptic
seizures prior to surgical treatment. In this analysis, we examined
the prevalence and predictors of postoperative seizures and the
prognostic signiﬁcance of postoperative seizure on progression-
free survival and overall survival.
2. Methods
2.1. Patients
We retrospectively identiﬁed all patients with preoperative
seizure who were 17 years of age or older; who demonstrated
biopsy-proven anaplastic astrocytoma (AA), anaplastic oligoden-
droglioma (AO), anaplastic oligoastrocytoma (AOA), and glioblas-
toma multiforme (GBM) from the Chinese Glioma Genome Atlas
(CGGA); and who underwent surgical resection at the Glioma
Treatment Center of Beijing Tiantan Hospital from January 2006 to
July 2013. Histological diagnosis was reafﬁrmed by two indepen-
dent neuropathologists and graded according to the WHO
classiﬁcation. Cases with discrepancies were re-reviewed by
another pathologist until a consensus was reached. Based on
these criteria, we included a total of 147 patients. The clinical
characteristics of the patients, which were systematically collectedat the time of histopathological diagnosis from medical records,
were the following: patient’s age at diagnosis, sex, type of seizure
(simple partial, complex partial and generalized seizures), tumour
location, extent of resection, pathological examinations, and
adjuvant therapy. The overall survival (OS) time, deﬁned as the
period from surgery to death, was collected when the patients
visited the clinics and during phone interviews with the patients
and/or their relatives. Progression-free survival (PFS) was deﬁned
as the time from surgery to image progression (appearance of a
new lesion or 25% increase in tumour size).
The enrolment criteria included the following: age of at least 17
years, histologically conﬁrmed anaplastic glioma or glioblastoma,
occurrence of preoperative seizure and patient’s consent. Patients
who only underwent biopsy and those who were lost to follow-up
or who had died of non-primary diseases were excluded. This
study was approved by the Ethics Committee of Beijing Tiantan
Hospital, and written informed consent was obtained from all of
the patients.
2.2. Assessment and measurements of seizure outcome
The primary outcome variable was seizure status, which was
evaluated after surgery using the Engel Classiﬁcation of Seizures:
class I = free of disabling seizures (completely seizure free; non-
disabling, simple partial seizures only; some disabling seizures but
free of disabling seizures for at least 2 years; generalized
convulsion with AED withdrawal only); class II = rare disabling
seizures (initially free of disabling seizures but rare seizures at the
time of study; rare disabling seizures since surgery; more than rare
disabling seizures but rare seizures for at least 2 years; nocturnal
seizures only); class III = worthwhile improvement (worthwhile
seizure reduction; prolonged seizure-free intervals amounting to
more than half of the follow-up period but not less than 2 years);
and class IV = no worthwhile improvement (no signiﬁcant seizure
reduction; no appreciable change; worse seizures). We divided the
patients with preoperative seizure into two groups based on the
epileptic outcome after surgery: 53 patients (36%) were complete-
ly seizure-free (Engel class I), whereas 94 patients (64%)
experienced postoperative seizures (Engel classes II, III, and IV).
The use of AEDs was based on the clinician’s preference. All of the
selected 147 patients experienced a preoperative seizure and took
sodium valproate for seizure prophylaxis prior to surgery. After
surgery, these patients typically continued AED treatment for 3–6
months and were gradually weaned off the medication. If the
patients had any evidence of seizures, the AED treatment was
continued.
2.3. Samples
Tumour tissue samples were obtained by surgical resection.
Resected specimens were snap-frozen and stored in liquid nitrogen
until DNA extraction or parafﬁn-embedding.
2.4. DNA extraction
The genomic DNA from frozen tumour tissues was isolated
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. The DNA concentration
and quality were measured using a NanoDrop ND-1000 spectro-
photometer (Nano-Drop Technologies, Houston, TX, USA).
2.5. Molecular evaluations
All of the data from the CGGA (Chinese Glioma Genome Atlas)
for which biomaterial was available were obtained. Immunohis-
tochemistry staining was performed for seven routinely tested
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IDH1/2 mutation), MGMT promoter methylation (DNA pyro-
sequencing), and expression of Ki-67, EGFR, TP53, PTEN, and
MGMT (immunohistochemistry) were assessed according to
routine methods [16]. Because different molecular markers have
different staining patterns and non-nuclear staining is generally
stronger than nuclear staining, the cutoff points for dichotomiza-
tion analyses were deﬁned as follows: active immunohistochemi-
cal staining for TP53, Ki67, EGFR, and PTEN was represented using a
scale of 0–3 (0–1 = low, 2–3 = high expression), and MGMT, which
shows non-nuclear staining, was deﬁned as 0–2 for low or 3 for
high expression (Fig. 1) [3].
3. Assessment of the extent of resection
The extent of resection was retrospectively classiﬁed from
reports on MRIs performed either 3 months postoperative or less
than 72 h after resection. Resection was deﬁned as biopsy (<10%
resection) or as partial (10–50%), subtotal (51–90%) or total (91–
100%) resection. All of our selected patients had undergone more
than 50% resection. Thus, we divided the patients into two groups:
the subtotal resection group and the total resection group. All of
the characteristics described above were assessed by an indepen-
dent neuroradiologist who was blinded to the patient outcome.
3.1. Tumour location
The tumour location was considered the lobe or region of the
brain within which the bulk of the glioma resided. These
assignments were based on an evaluation of medical records
and imaging study results, mainly MRI characteristics, including
tumour side (left, right, or bilateral) and speciﬁc lobe involvement
(frontal, temporal, parietal, occipital, and insula).
3.2. Follow-up
Survival data were collected by clinics during patient visits and/
or phone interviews. Patients who underwent biopsy only were
not followed up at our centre and were subsequently excluded
from the survival analysis.Fig. 1. Photomicrographs of tumour tissue with high and low levels of MG3.3. Statistical analysis
All statistical analyses were performed using SPSS version 13.0
(SPSS, Chicago, IL, USA) and were tailored to address associations
between the presence of preoperative seizures and clinicopatho-
logical characteristics and survival outcomes. Survival function
curves were calculated using the Kaplan–Meier method, and
differences were evaluated using the log-rank test. Univariate
analyses were performed using the Chi-square test for dichoto-
mous variables. All of the variables that were found to be
associated with postoperative seizures through the Chi-square
analysis (P < 0.05) were included in a backward stepwise logistic
regression model. A probability value of 0.05 obtained after two-
sided P-values were computed was considered statistically
signiﬁcant.
4. Results
We identiﬁed patients with preoperative seizure who had
undergone primary resection of cerebral high-grade glioma
(HGGs) from 2006 to July 2013 from the CGGA database. Basic
information of all of the included patients is included in Table 1.
We found 147 patients (age range, 17–76 years; median age, 43
years) with preoperative seizure who were at least 17 years of age
and who had WHO grade III or IV tumours. Among these patients,
81 were male, and 66 were female. The patients were divided into
two groups as follows: 72 and 75 patients with tumours with and
without AO/AOA, respectively. In addition, 98 patients underwent
radiotherapy, and 81 patients underwent chemotherapy. In our
dataset, the percentage of patients accepting radiotherapy was
only 67%. Although radiotherapy is a treatment applied for HGGs
after surgery, the economic condition, equipment condition and
patients’ compliance can affect the number of patients who
underwent radiotherapy after surgery. With regard to MRI
characteristics, the most commonly involved lobe was the frontal
(69%), followed by the temporal (38%), insula (19%), and parietal
(11%) lobes. Forty-nine tumours were located in the left cerebral
hemisphere, 54 were localized in the right cerebral hemisphere,
and six were located bilaterally. According to their clinical
symptoms, 76 (60%) patients exhibited secondary generalized
seizures, 42 (33%) exhibited simple partial seizures, and nine (7%)MT and EGFR expression, as detected through the staining intensity.
Table 1
Clinical and demographic characteristics of 147 patients.
Variable Total Postoperative seizure P-value
N = 147 Yes (n = 53) No (n = 94)
Sex Male 81(55.1) 28(50.9) 53(57.6) 0.429
Female 66(44.9) 27(49.1) 39(42.4)
Age 43 72(51.1) 21(41.2) 51(56.7) 0.077
<43 69(48.9) 30(58.2) 39(43.3)
NA 6
Histology AO/AOA 71(48.6) 32(60.4) 40(42.6) 0.038
AA/GBM 75(51.4) 21(39.6) 54(57.4)
NA 1
Tumour involvement Frontal 76(68.5) 29(49.2) 47(49.0) 0.234
Temporal 42(37.8) 15(25.4) 27(28.1) 0.798
Parietal 12(10.8) 5(8.5) 7(7.3) 0.801
Occipital 4(3.6) 0(0) 4(4.2) 0.351
Insula 21(18.9) 10(16.9) 11(11.5) 0.161
Tumour side Left 49(45.0) 19(50) 30(42.3) 0.438
Right 54(49.5) 18(47.4) 36(50.7) 0.793
Bilateral 6(5.5) 1(2.6) 5(7.0) 0.602
NA 38
Seizure type Secondary generalized 76(59.8) 25(56.8) 51(61.4) 0.613
Simple partial 42(33.1) 17(38.6) 25(29.8) 0.332
Complex partial 9(7.1) 2(4.5) 7(8.3) 0.653
NA 20
IDHmut MT 56(53.8) 20(51.3) 36(55.4) 0.685
WT 48(46.2) 19(48.7) 29(44.6)
NA 43
MGMTmeth MT 45(55.6) 17(63.0) 28(51.9) 0.343
WT 36(44.4) 10(37.0) 26(48.1)
NA 66
MGMTexp High 20(14.6) 2(4.2) 18(20.2) 0.011
Low 117(85.4) 46(95.8) 71(79.8)
NA 10
Ki67exp High 63(47.0) 20(40.8) 43(50.6) 0.275
Low 71(53.0) 29(59.2) 42(49.4)
NA 13
EGFRexp High 50(36.5) 8(16.7) 42(47.2) 0.0004
Low 87(63.5) 40(83.3) 47(52.8)
NA 10
TP53exp High 54(39.4) 17(35.4) 37(41.6) 0.482
Low 83(60.6) 31(64.6) 52(58.4)
NA 10
PTENexp High 69(57.5) 19(50.0) 50(69.4) 0.045
Low 51(42.5) 19(50.0) 22(30.6)
NA 27
Resection Total 72(52.6) 29(56.9) 43(50.0) 0.437
Subtotal 65(47.4) 22(43.1) 43(50.0)
NA 10
Radiotherapy Yes 98(79.0) 38(80.9) 60(77.9) 0.698
No 26(21.0) 9(19.1) 17(22.1)
NA 23
Chemotherapy Yes 81(65.3) 32(68.1) 49(63.6) 0.614
No 43(34.7) 15(31.9) 28(36.4)
NA 20
AO: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; AA: anaplastic astrocytoma; GBM: glioblastoma multiforme; MT: mutational type; WT: wild type;
IDHmut: isocitrate dehydrogenase mutation; MGMTmeth: O6-methylguanine DNA-methyltransferase promoter methylation; MGMTexp: O6-methylguanine DNA-
methyltransferase protein expression; Ki67: a protein which in humans is encoded by the MKI67 gene; EGFRexp: epidermal growth factor receptor protein expression;
TP53exp: a transcription factor protein which in humans is encoded by the TP53 gene; PTENexp: phosphatase and tensin homolog deleted on chromosome 10.
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were lost to follow up.
As shown in Fig. 1, we selected four photomicrographs of
tumour tissue stained for MGMT and EGFR with different scores.
We selected seven biomarkers that may be connected with
postoperative seizure. As shown in Fig. 2, among patients withpostoperative seizure, there were 20 (51%) patients with an IDH1
mutation, 17 (63%) with MGMT promoter methylation, eight (17%)
patients with high EGFR expression, 17 (35%) patients with high
TP53 expression, 19 (50%) patients with high PTEN expression, two
(4%) patients with high MGMT expression, and 20 (41%) patients
with high Ki-67 protein expression.
Fig. 2. Expression of seven biomarkers in patients with and without postoperative
seizure.
Table 3
Survival rate of patients with and without postoperative seizure.
Postoperative seizure No postoperative
seizure
Fig. 3. Kaplan–Meier curve demonstrating the survival of patients with and without
postoperative seizure.
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To identify factors associated with postoperative seizure, we
compared the demographic and tumour information between
patients with and without seizure (see Table 1 for a complete list).
The Chi-square analysis revealed four variables that were
signiﬁcantly associated with the presence of seizures: AO/AOA (yes
vs. no, P = 0.038, Chi-square test), EGFR expression (high expres-
sion vs. low expression, P = 0.0004), MGMT expression (high
expression vs. low expression, P = 0.011), and PTEN expression
(high expression vs. low expression, P = 0.045). The logistic
regression analysis found that three out of the four variables
were strongly associated with postoperative seizures: tumours
with AO/AOA, low MGMT expression, and low EGFR expression
were independent factors for a higher incidence of postoperative
seizures (P-values, odds ratios, and 95% conﬁdence intervals are
shown in Table 2).
6. Prognostic value of postoperative seizures in high-grade
gliomas
Of the 147 high-grade glioma patients (as shown in Fig. 3),
patients with postoperative seizures had a longer OS and PFS
compared with those without seizures (median 837 days vs. 670
days and 482 days vs. 390 days), but this difference was not
statistically signiﬁcant (P = 0.275 and P = 0.146; Fig. 3). As shown
in Table 3, we found that the survival rate of patients with
postoperative seizure was higher than that of those without
postoperative seizure. With the passage of time, the survival rate of
the two groups became closer in value.
7. Discussion
A total of 53 (36%) patients with postoperative seizure were
included in our study, which is consistent with ﬁndings obtained in
previous studies, whereas the cohort included 94 (64%) patients
who did not suffer from postoperative seizure. In recent years,Table 2
Multivariate predictors of postoperative seizure control after surgery.
Variable Odds ratio 95%Cl P value
AO/AOA 2.566 1.010 6.519 0.048
MGMTexp 0.186 0.034 1.018 0.05
EGFRexp 0.127 0.038 0.424 0.001
AO: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; MGMTexp:
O6-methylguanine DNA-methyltransferase protein expression; EGFRexp: epider-
mal growth factor receptor protein expression.several prognostic variables have consistently been shown to be
important in patients with GBM [20]. We assumed that the
biological behaviour and the clinical factors of gliomas may, to
some extent, be related to the presence of seizures. Thus, we
retrospectively analysed a set of 147 patients with preoperative
seizure to identify the clinical factors and biological behaviour
associated with postoperative seizure and to assess the prognostic
importance of postoperative seizure.
Seizure is common in patients with brain tumours and can
substantially affect daily life, even if the tumour is under control
[21]. The mechanisms underlying brain tumour-related epilepsy
are most likely multifactorial because different biochemical and
morphological changes in the peritumoural brain parenchyma are
likely involved. The expansive growth of tumours can suppress
peripheral tissues, which play an important role in the genesis ofOS Median (days) 826 696
6 months (%) 86 74
12 months (%) 66 58
24 months (%) 46 44
36 months (%) 37 38
PFS Median (days) 536 431
6 months (%) 66 56
12 months (%) 50 41
24 months (%) 38 29
36 months (%) 23 22
OS: overall survival; PFS: progress-free survival.
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tumour microenvironment [22]. It is well known that LGGs, which
show expansive growth, can suppress peri-tissues more gravely
than HGGs, which exhibit inﬁltrative growth. Thus, the incidence
of seizures is higher in LGGs than HGGs.
It is also well established that seizures are more difﬁcult to
control in HGGs than in LGGs, but few studies on seizures in HGGs
are available in the literature. There were three authoritative
studies about epileptic seizures in LGGs. Comparatively speaking,
the strength of this study lies in the following: (1) it has a novel
research direction regarding seizures in HGGs; (2) the study
focuses on the postoperative seizure control of 147 patients with
preoperative seizure; (3) the study selected patients taking sodium
valproate as an AED before surgery and subjected to the regular
application of AED after surgery to eliminate drug interference; (4)
data from CGGA were homogeneously collected; and (5) the study
included multiple variables of interest, such as molecular markers.
The median age of the patients included in our study was 43
years. In contrast to other studies, age was not found to be a
predictive factor for postoperative seizure control [4]. Consistent
with our ﬁndings, Ozbek et al. showed that gender did not predict
survival outcome (P = 0.429) [4]. There is no clear consensus
concerning the extent of surgical resection in the current literature
[4]. Miller et al. [23] suggested that the extent of surgery could
predict seizure outcome. In their study, subtotal (P = 0.007) and
total (P < 0.001) resections were found to serve as independent
predictors of total epileptic seizure control after oncological
treatment. Vecht et al. [24] and Shibamoto et al. [25] showed that
extensive surgery was correlated with a longer survival time
compared with limited surgery. However, in our study, we did not
identify any difference in the postoperative seizure incidence
between total resection and subtotal resection (P = 0.437). It is well
known that the expansive growth of tumours can suppress
peripheral tissues, which play an important role in the genesis
of seizures. The total resection of tumours can relieve the
suppression of tissues better than subtotal resection. However,
our data showed that the subtotal resection mean removed 80% of
the tumour location, indicating that subtotal resection exerted an
effect on reducing pressure that was similar to that of total
resection.
The ﬁndings obtained in previous studies are consistent with
the results obtained in our study, demonstrating that oligoden-
droglial tumours are the most common tumour types that present
with seizure [5]. Moreover, the logistic regression analysis
revealed that AO/AOA can affect postoperative seizure control in
an independent manner (P = 0.048).
The correlation between biomarkers and postoperative seizure
has been one of the most popular research areas over the past two
decades. Some predicted genetic and molecular tumour marker
data have been published [18,26]. Nevertheless, little is known
regarding how changes in genetic and molecular expression can
affect tumour-related postoperative seizure control. In our studies,
seven routinely tested molecular markers were selected to predict
the outcome of postoperative seizure control. We found that the
MGMT methylation and IDH1 mutation could not predict the
incidence of postoperative seizures (P = 0.685). These ﬁndings are
in contrast to the results obtained in an earlier study by Yang et al.,
who found an association between the expression of Ki67 and the
occurrence of preoperative seizure in grade III glioma [3]. However,
we found that Ki67 could not predict postoperative seizure in
grade III and IV tumours (P = 0.275). Moreover, consistent with the
study conducted by Gan You, no association was found between
tumour location and the incidence of postoperative seizure.
However, for this seizure type, we could not identify an association
with postoperative seizure. The Chi-square analysis revealed that
the expression of EGFR, PTEN, and MGMT can predict theoccurrence of postoperative seizure (P = 0.0004, P = 0.045, and
P = 0.011, respectively). In addition, the logistic regression analysis
found that only the expression of MGMT and EGFR was statistically
signiﬁcant (P = 0.05 and P = 0.001). Thus, patients with lower
expression of MGMT and EGFR more frequently experienced
postoperative seizures.
Another study conducted by Wang et al. [27] found that the
GBMO (glioblastoma oligodendroglioma) group showed more
frequent preoperative seizure occurrence, higher rates of IDH1
mutation, lower MGMT expression, and longer survival, support-
ing our hypothesis that AO/AOA may also increase the incidence of
postoperative seizure. LGGs are more strongly associated with
seizures than HGGs. In conclusion, we found that the AO/AOA
group was associated with an increased incidence of tumour-
related postoperative seizure.
The DNA repair protein MGMT, which is located on chromosome
10q26, is an important tumour-related biomarker [27]. We found a
relationship between MGMT protein expression and factors
associated with postoperative seizure. Previous studies have shown
that tumours with lower MGMT protein expression are more
sensitive to radiotherapy and chemotherapy and that GBM patients
with lower MGMT protein expression lived longer lives [28]. Low
MGMT protein expression is indicative of a more benign tumour.
Previous studies have shown that benign tumours (expansive
growth) are more associated with tumour-related seizures com-
pared with malignant tumours (invasive growth). Thus, in this study,
high MGMT protein expression may indicate that the tumours are
more malignant and that these malignant tumours are less
associated with tumour-related postoperative seizure.
EGFR is a tyrosine kinase that dimerises upon binding to
extracellular EGF and mediates signal transduction. This signal
elicits a downstream cascade via the mitogen-activated protein
kinase/extracellular signal-regulated kinase and phosphatidylino-
sitol 3-kinase/Akt pathways, which generally promote growth and
cell migration. Although such signalling is critical for normal
organism development, glioma cells frequently use EGFR signalling
to promote tumour behaviour. Gliomas employ several methods to
upregulate EGFR signalling, including overexpression of the receptor
via disrupted regulatory feedback, thereby sensitising the cell to
extracellular EGF. Other methods include overexpression via EGFR
gene ampliﬁcation on 7p12 and generation of a truncation mutation,
which produces a constitutively active EGFRvIII. The level of EGFR
expression is dependent on the grade of the glioma. The level of EGFR
expression in HGGs is also higher than that in LGGs. Thus, a tumour
with high EGFR protein expression is more malignant, which may
account for the low incidence of postoperative seizure in the HGGs
with high EGFR protein expression. Thus, the difference in the
expression proﬁles obtained between different grades likely
accounts for this result [5]. The immunohistochemical (IHC) results
obtained for MGMT and EGFR substantiate our results. High protein
expression of MGMT and EGFR can make a tumour more malignant
in different ways.
Despite medical and surgical advances, the prognosis of
patients with HGG remains poor. Irradiation and chemotherapy
are common treatments. However, our studies revealed no
difference between postoperative seizure control and radiother-
apy and chemotherapy. In summary, seizures are a major
issue for patients with HGGs that signiﬁcantly affects the
patients’ quality of life. This study found that high levels of
MGMT and EGFR expression predispose patients to a favourable
outcome in terms of postoperative seizure. Furthermore, the AO/
AOA group showed more frequent instance of postoperative
seizures. Thus, the expression of MGMT and EGFR and tumours
with AO/AOA provide insights into the development of effective
treatment strategies aimed at predicting the prognosis of
patients with HGGs.
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